For clinicians and patients alike, the word "indeterminate" is the most frustrating outcome in HIV testing. It is a diagnostic limbo: the initial screening test is reactive, but the confirmatory assay fails to provide a clear "positive" or "negative" result. This ambiguity triggers a cascade of delays, anxiety, and additional testing requirements that can stall life-saving clinical decisions.

New research from Qatar University, published in Scientific Reports, suggests that the root of this problem often lies in the specific way older confirmatory assays interpret isolated protein bands. By comparing the widely used INNO-LIA HIV I/II Score with the Mikrogen recomLine HIV-1/2 IgG assay, researchers have identified that many "indeterminate" results are likely artifacts of incomplete antibody responses rather than true infections.

The Problem with Isolated gp41 Reactivity

Confirmatory line immunoassays work by detecting antibodies against specific HIV antigens—proteins like gp160, gp120, and gp41. A definitive positive result requires a specific combination of these bands to be present. However, many patients show reactivity to only one or two bands, most commonly gp41.

In the study of 180 serum samples, the INNO-LIA assay produced indeterminate results in 13.3 percent of cases, largely due to this isolated gp41 reactivity. When the same samples were retested using the recomLine assay, the rate of indeterminate results dropped to just 2.8 percent. The researchers found that the recomLine assay successfully reclassified 85 percent of the samples that were previously labeled "indeterminate" by INNO-LIA. Crucially, all of these reclassified samples were confirmed negative via HIV-1 RNA PCR testing.

Why Antigen-Band Patterns Matter

This discrepancy highlights a fundamental challenge in diagnostic design: sensitivity versus specificity. If an assay is tuned to be hyper-sensitive to any hint of an HIV protein, it will inevitably flag non-specific cross-reactivity as "indeterminate."

"The findings provide insights into mechanisms underlying indeterminate HIV serology, suggesting that incomplete or isolated antigenic responses, particularly gp41, are major contributors," the authors noted. By refining how these assays read the antigen-band patterns, laboratories can significantly reduce the number of patients left in diagnostic uncertainty.

Clinical Implications for Diagnostic Workflows

Reducing indeterminate results is not just a technical win; it is a clinical necessity. Every indeterminate result necessitates follow-up testing, often involving molecular methods like HIV-1 RNA PCR. While PCR is highly accurate, it is also more expensive and time-consuming than standard serological assays.

By adopting assays that demonstrate higher specificity in interpreting these band patterns, diagnostic labs can streamline their workflows. This shift allows for faster reporting, which is essential for patients who require immediate linkage to care or for those who need the peace of mind that a negative result provides.

Key Takeaways

  • Reducing Ambiguity: The recomLine HIV-1/2 IgG assay significantly reduced indeterminate results compared to the INNO-LIA assay (2.8% vs 13.3%).
  • The gp41 Factor: Isolated reactivity to the gp41 antigen is the primary driver of indeterminate results in standard confirmatory line immunoassays.
  • PCR Validation: Reclassified samples from the study were confirmed negative by HIV-1 RNA PCR, suggesting that many indeterminate results are false alarms caused by non-specific antibody binding.

The Next Step in Diagnostic Standardization

While this study provides a clear path forward for improving the accuracy of confirmatory testing, the broader challenge remains the standardization of these assays across different global health systems. As laboratories look to update their testing algorithms, the focus will likely shift toward integrating these more precise antigen-band interpretation methods. The next major decision point for public health departments will be whether to update their national testing guidelines to favor assays that demonstrate this higher specificity, potentially saving thousands of patients from the unnecessary stress of an indeterminate result in the coming fiscal year.